SCHEMBL10043847

SCHEMBL10043847

Cc1cc2c(cn1)cc(-c1cc(NC(=O)Nc3cccc(C(F)(F)F)c3)ccc1C)c(=O)n2C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.59
KDR P35968 5/20 0.55
LCK P06239 4/20 0.55
MAPK14 Q16539 3/20 0.55
JAK3 P52333 3/20 0.55
TEK Q02763 1/20 0.55
DDR2 Q16832 1/20 0.52
MAPT P10636 2/20 0.49
NPC1 O15118 1/20 0.49
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
BRAF P15056 1/20 0.47
TNNI3K Q59H18 1/20 0.47
IDH1 O75874 3/20 0.47
AURKB Q96GD4 2/20 0.46
AURKA O14965 1/20 0.46
NTRK1 P04629 2/20 0.46
NTRK2 Q16620 2/20 0.46
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043852 0.90 SYK (0.62) SYKKDRLCKMAPK14JAK3
SCHEMBL10043698 0.90 SYK (0.70) SYKKDRLCKMAPK14JAK3
SCHEMBL10043848 0.90 SYK (0.48) SYKKDRLCKMAPK14JAK3
SCHEMBL10043839 0.88 SYK (0.47) SYKKDRLCKMAPK14JAK3
SCHEMBL10043821 0.88 SYK (0.49) SYKKDRLCKMAPK14JAK3
SCHEMBL10043860 0.86 SYK (0.51) SYKKDRLCKMAPK14JAK3
SCHEMBL10043828 0.86 RAB9A (0.48) SYKMAPK14MAPTNPC1BRAF
SCHEMBL10043845 0.86 SYK (0.45) SYKKDRLCKBRAFAURKB
SCHEMBL10043846 0.85 KDR (0.49) SYKKDRLCKMAPK14JAK3
SCHEMBL10072021 0.85 SYK (0.59) SYKKDRLCKMAPK14JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885KDR 108/4885LCK 4/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885KDR 108/4885LCK 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.